大鼠脐带来源间充质干细胞生物学特性及其对移植免疫耐受作用的研究
|
摘要
间充质干细胞(MScs)是来源于发育早期中胚层的一类多能干细胞,在诱导器官移植免疫耐受中有着广阔的应用前景。目前MSCs主要来源于成人骨髓,但许多研究显示人脐带是较理想的MSCs来源。关于大鼠骨髓来源的MSCs用于移植免疫耐受及进行组织修复的研究很多,但由于没有大鼠脐带来源MSCs的相关研究,导致脐带来源的MSCs无法进行动物体内试验。本研究从大鼠脐带中分离出间充质干细胞,并对其生物学特性进行研究,找到合适的分离培养方法,并进行体外和体内试验,探讨脐带源间充质干细胞减少免疫排斥反应,诱导免疫耐受的作用。
本研究第一部分采用胶原酶消化法和组织块培养法,进行贴壁传代,得到大鼠脐带源间充质干细胞,进行细胞表型分析和诱导分化。结果显示：两种方法得到的贴壁细胞均为间充质干细胞,其生物学性状与文献报导的骨髓间充质干细胞很接近。胶原酶消化法比组织块培养法的效率更高。第二部分以Lewis大鼠脾细胞为反应细胞,DA大鼠脾细胞为刺激细胞,加入来源于Wistar大鼠脐带的间充质干细胞,采用3H-胸腺嘧啶核苷掺入法,进行混合淋巴细胞培养,检测大鼠骨脐带来源充质干细胞对体外混合淋巴细胞培养的影响。结果显示脐带来源间充质干细胞不引起大鼠淋巴细胞增殖反应,但对大鼠混合淋巴细胞培养有显著的抑制作用；第三部分以DA大鼠为供体,Lewis大鼠为受体,建立大鼠异位心脏移植模型,并于术后即刻经尾静脉注入Wistar大鼠脐带来源的间充质干细胞,探讨其对大鼠同种异体心脏移植的影响。异位心脏移植后受体鼠分成2组。1、空白对照组经尾静脉注射生理盐水；2、试验组经尾静脉注射第三方大鼠脐带间充质干细胞；结果显示,移植心脏的存活时间为组1：7.5±0.5天；组2：14.8±2.1天。统计学分析显示,移植心脏存活时间组2比组1明显延长(p<0.05)。
本研究结果表明,采用消化法和组织块培养法均能够从大鼠的脐带中获得间充质干细胞,消化法的效果更佳,脐带源间充质干细胞作为第三方细胞,能够在体外抑制淋巴细胞的增殖,并能够在体内延长同种异体心脏移植物的存活时间和减轻排斥反应。
Mesenchymal stem cells(MSCs) are multipotential stem cells derived from mesoderm of early phase embryo. It possesses wide application perspective for inducing immunotolerance in organ transplantation. Now MSCs are mainly derived from the adult bone marrow., but many studies showed that human umbilical cord was the better sorce of mesenchymal stem cells. There are many studies that MSCs derived from rat bone marrow were used for transplantation immune tolerance and tissue repair. But because of no correlated study for MSCs derived from rat umbilical cord, study for MSCs derived from umbilical cord could not be done in vivo. In our study, we isolated MSCs from rat umbilical cord and studied their biological characteristics. At last we find a suitable method for isolating and culturing Mscs. We did experiments in vitro and in vivo to study thei effect for inducing immunotolerance and softening immunological rejection.
In first part of our study, we successfully isolated MSCs from rat umbilical cord by two enzyme method and tissue mass method.Then we analyzed the cells phenotype and induced cell differentiation Results showed that adherent cells obtained through two methods were all MSCs. Their biological character were the same with MSCs'form bone marrow reported in literature. Two enzyme method was better then tissue mass method. In second part of our study, we choosed Lewis rat's spleen cells as react cells and DA rat's spleen cells as stimulate cells. Then MSCs form Wistar rat's umbilical cord were added in them. Methods By the means of 3H-TdR (three tritium thymine deoxyribosid), we do the MLC(mixed lymphocyte culture) experiments to detect whether the MSCs from rat umbilical cord affected MLC. Results showed that MSCs from rat umbilical cord could not cause rats lymphproliferation response, but have a notable suppressing effect in MLC. In third part of our study, we choosed DA rat as donor and lewis rat as recipient, to establish a heterotopic model of rat heart transpalntation and after orperation immediately inject MSCs from Wistar rat umbilical cord. We investigated the influence of MSCs on allograft of rat heart transplantation In this part,all recepients were divided into two groups. In control group,recepients received normal saline via tail vein after transplantation. In experimental group Recepients received third party MSCs via tail vein. Results showed that the surviving time of transplanted hearts in control group and in experimental group was 7.5±0.5 days and 14.8±2.1 days. Statistical analysis showed that it was longer in experimental group than that in control group(p<0.05).
Our research showed that we could get a plenty of MSCs from rat umbilical cord through two enzyme method and tissue mass method. Two enzyme method was better then tissue mass method. As a third party cell, MScs from umbilical cord could suppress lymphocyte proliferation in vitro, and prolong xenograft survival and soften immunological rejection in vivo.
本研究第一部分采用胶原酶消化法和组织块培养法,进行贴壁传代,得到大鼠脐带源间充质干细胞,进行细胞表型分析和诱导分化。结果显示：两种方法得到的贴壁细胞均为间充质干细胞,其生物学性状与文献报导的骨髓间充质干细胞很接近。胶原酶消化法比组织块培养法的效率更高。第二部分以Lewis大鼠脾细胞为反应细胞,DA大鼠脾细胞为刺激细胞,加入来源于Wistar大鼠脐带的间充质干细胞,采用3H-胸腺嘧啶核苷掺入法,进行混合淋巴细胞培养,检测大鼠骨脐带来源充质干细胞对体外混合淋巴细胞培养的影响。结果显示脐带来源间充质干细胞不引起大鼠淋巴细胞增殖反应,但对大鼠混合淋巴细胞培养有显著的抑制作用；第三部分以DA大鼠为供体,Lewis大鼠为受体,建立大鼠异位心脏移植模型,并于术后即刻经尾静脉注入Wistar大鼠脐带来源的间充质干细胞,探讨其对大鼠同种异体心脏移植的影响。异位心脏移植后受体鼠分成2组。1、空白对照组经尾静脉注射生理盐水；2、试验组经尾静脉注射第三方大鼠脐带间充质干细胞；结果显示,移植心脏的存活时间为组1：7.5±0.5天；组2：14.8±2.1天。统计学分析显示,移植心脏存活时间组2比组1明显延长(p<0.05)。
本研究结果表明,采用消化法和组织块培养法均能够从大鼠的脐带中获得间充质干细胞,消化法的效果更佳,脐带源间充质干细胞作为第三方细胞,能够在体外抑制淋巴细胞的增殖,并能够在体内延长同种异体心脏移植物的存活时间和减轻排斥反应。
Mesenchymal stem cells(MSCs) are multipotential stem cells derived from mesoderm of early phase embryo. It possesses wide application perspective for inducing immunotolerance in organ transplantation. Now MSCs are mainly derived from the adult bone marrow., but many studies showed that human umbilical cord was the better sorce of mesenchymal stem cells. There are many studies that MSCs derived from rat bone marrow were used for transplantation immune tolerance and tissue repair. But because of no correlated study for MSCs derived from rat umbilical cord, study for MSCs derived from umbilical cord could not be done in vivo. In our study, we isolated MSCs from rat umbilical cord and studied their biological characteristics. At last we find a suitable method for isolating and culturing Mscs. We did experiments in vitro and in vivo to study thei effect for inducing immunotolerance and softening immunological rejection.
In first part of our study, we successfully isolated MSCs from rat umbilical cord by two enzyme method and tissue mass method.Then we analyzed the cells phenotype and induced cell differentiation Results showed that adherent cells obtained through two methods were all MSCs. Their biological character were the same with MSCs'form bone marrow reported in literature. Two enzyme method was better then tissue mass method. In second part of our study, we choosed Lewis rat's spleen cells as react cells and DA rat's spleen cells as stimulate cells. Then MSCs form Wistar rat's umbilical cord were added in them. Methods By the means of 3H-TdR (three tritium thymine deoxyribosid), we do the MLC(mixed lymphocyte culture) experiments to detect whether the MSCs from rat umbilical cord affected MLC. Results showed that MSCs from rat umbilical cord could not cause rats lymphproliferation response, but have a notable suppressing effect in MLC. In third part of our study, we choosed DA rat as donor and lewis rat as recipient, to establish a heterotopic model of rat heart transpalntation and after orperation immediately inject MSCs from Wistar rat umbilical cord. We investigated the influence of MSCs on allograft of rat heart transplantation In this part,all recepients were divided into two groups. In control group,recepients received normal saline via tail vein after transplantation. In experimental group Recepients received third party MSCs via tail vein. Results showed that the surviving time of transplanted hearts in control group and in experimental group was 7.5±0.5 days and 14.8±2.1 days. Statistical analysis showed that it was longer in experimental group than that in control group(p<0.05).
Our research showed that we could get a plenty of MSCs from rat umbilical cord through two enzyme method and tissue mass method. Two enzyme method was better then tissue mass method. As a third party cell, MScs from umbilical cord could suppress lymphocyte proliferation in vitro, and prolong xenograft survival and soften immunological rejection in vivo.
引文
1. SayeghMH, Carpenter CB. Transplantation 50 Years Later Progress,Challenges and Promises. N Engl J Med.2004,351 (26):2761-2766.
2. Jiang Y, Jahagirdar BN, Reinhardt RL,et al.Pluripotency of mesenchymal stem cells derived from adult marrow.Nature.2002,418(6893):41-9.
3. Pittenger MF,Martin BJ.Mesenchymal stem cells and their potential as cardiac therapeutics.Circ Res 2004,95(1):9-20.
4. Schwartz RE,Reyes M,Koodie L,et al.Mutipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells.J Clin Invest 2002,109(10):1291-1302.
5. Satake K,Lou J,Lenke LGMigration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue. Spine 2004, 29(18):1971-1979.
6. DEANS R J, MOSEL EY A B. Mesenchymal stem cells:Biology and potential clinical uses[J]. Exp Hematol,2000,28(8):875-884.
7. TSEW T, PENDL ETON J D, BEYER W M, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells:implications in ransplantation. Transplantation,2003,75(3):389-397.
8..KL YUSHNEN KOVA E, SHUSTOVA V, MOSCA J D, et al. Human mesenchymal stem cells induce unresponsiveness in preactivated but not naive alloantigen specific T cells [J]. Exp Hematol,1999,27(30:122-122.
9. Le BLANC K, TAMMIK L, SUNDBERG B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol,2003,57(1):11-20.
10.唐伟,马建波,张陶然等.供体骨髓细胞输注促进小鼠皮肤移植耐受及其机理的研究.中华微生物学和免疫学杂志2003,23(2)：143-147。
11.张庆殷,郝洁,郭宏伟等.门静脉输注供体脾细胞诱导异基因大鼠心脏移 植耐受.免疫学杂志2001,17(4)：247-250.
12. Han Q,Deng W,Li C,et al.Allogeneic adult stem cells establish long-term residence in recipient tissues and facilitate skin transplantation.Exp Hematol 2003,31(9):158-159.
13. Rao MS,Matton MP. Stem cells and aging expanding the possibilities.Mech Ageing Dev 2001,122(7):713-734.
14. Barry FP, Murphy JM. Mesenchymal stem cells:clinical applications andbiological characterization.Int J Biochem Cell Biol 2004,36(4):568-84.
15. Hu Y,Liao LM,Wang QY,et al.Isolation and identification of mesenchymal stem cells from human fetal pancreas.J Lab Clin Med 2003,141(5):342-349.
16. In't Anker PS,Noort WA,Scherjon SA,et al.Mesenchymal stem cells in human second-trimester bone marrow,liver,lung,and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 2003,88(8):845-852.
17. Lee OK,Kuo TK,Chen WM,et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood.Blood 2004,103(5):1669-1675.
18. Romanov YA,Svintsitskaya VA,Smirnov VN.Searching for alternative sources of postnatal human mesenchymal stem cells:candidate MSC-like cells from umbilical cord.Stem Cells 2003,21(1):105-110.14.
19. Bartholomew A,Sturgeon C,Siatskas M,et al.Mesenchymal stem cells suppress 40 lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol 2002,30(1):42-48.
20. Wexler SA,Donaldson C,Denning-Kendall P,et al.Adult bone marrow is a rich source of human mesenchymal'stem'cells but umbilical cord and mobilized adult blood are not.Br J Haematol 2003,121(2):368-374.
21.吕璐璐,刘拥军,许贞书,等.脐带源间充质干细胞的分离和生物学形状.福建医科大学学报.2006.,40(2)：99-104.
22.张浪辉,刘拥军,吕璐璐,等.脐带源间充质干细胞对异源性脐带血T淋巴细胞激活与增殖的抑制作用[J].中国肿瘤生物治疗杂志,2006,13(3)： 191-195.
1. Sbano P, Cuccia A, Mazzanti B, et al.Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res.2008,300(3):115-24.
2. Itakura S, Asari S, Rawson J, et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant.2007,7(2):336-46.
3. Miyazaki M, Zuk PA, Zou J, et al. Comparison of human mesenchymal stem cells derived from adipose tissue and bone marrow for ex vivo gene therapy in rat spinal fusion model. Spine (Phila Pa 1976).2008,33(8):863-9.
4. Parr AM, Kulbatski I, Wang XH, et al. Fate of transplanted adult neural stem/progenitor cells and bone marrow-derived mesenchymal stromal cells in the injured adult rat spinal cord and impact on functional recovery.Surg Neurol.2008,70(6):600-7.
5. Zhang YH, Wang HF, Liu W, et al. Insulin-producing cells derived from rat bone marrow and their autologous transplantation in the duodenal wall for treating diabetes.Anat Rec (Hoboken).2009,292(5):728-35.
6. Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells:candidate MSC-like cells from umbilical cord. Stem Cells.2003,21(1):105-110.
7. Covas DT, Siufi JL, Silva AR, et al. Isolation and culture of umbilical vein mesenchymal stem cells. Braz J Med Biol Res.2003,36(9):1179-1183.
8. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells.2004,22(7):1330-1337.
9. Sarugaser R, Lickorish D, Baksh D, et al. Human umbilical cord perivascular (HUCPV) cells:a source of mesenchymal progenitors. Stem Cells,2005,23(2):220-229.
10. Ennis J, Gotherstrom C, Le Blanc K, et al. In vitro immunologic properties of human umbilical cord perivascular cells. Cytotherapy.2008,10(2):174-81
11. Hu Y, Liao L, Wang Q, et al. Isolation and identification of mesenchymal stem cells from human fetal pancreas. J Lab Clin Med.2003,141(5):342-349.
12. Anker PS, Noort WA, Scherjon SA, et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica.2003,88(8):845-852.
13. Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004,103(5):1669-1675.
14. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol.2002,30(1):42-48.
15. Wexler SA, Donaldson C, Denning-Kendall P, et al. Adult bone marrow is a rich source of human mesenchymal'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol.2003,121(2):368-374.
16.吕璐璐,刘拥军,许贞书,等.脐带源间充质干细胞的分离和生物学形状[J].福建医科大学学报,2006,40(2)：28-30.
17.张浪辉,刘拥军,吕璐璐,等.脐带源间充质干细胞对异源性脐带血T淋巴细胞激活与增殖的抑制作用[J].中国肿瘤生物治疗杂志,2006,13(3)：191-195.
18. Cao FJ, Feng SQ. Human umbilical cord mesenchymal stem cells and the treatmentof spinal cord injury. Chin Med J (Engl).2009,122(2):225-31.
19. Friedman R, Betancur M, Boissel L, et al. Umbilical cord mesenchymal stem cells:adjuvants for human cell transplantation. Biol Blood Marrow Transplant.2007,13(12):1477-86.
20. Yang CC, Shih YH, Ko MH, et al. Transplantation of humanumbilical mesenchymal stem cells from Wharton's jelly after complete transection of the rat spinal cord. PLoS One.2008,3(10):e3336.
21. Kadam SS, Tiwari S, Bhonde RR. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord. In Vitro Cell Dev Biol Anim.2009,45(1-2):23-7.
22. Ding DC, Shyu WC, Chiang MF, et al. Enhancement of neuroplasticity through upregulation of betal-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis.2007,27(3):339-53.
23. Qiu ZY, Yang SG, Chen ZP, et al. Mesenchymal stem cells derived from human umbilical cord tissue modulate thesecretion of antiplatelet antibody from splenocytes of ITP patients in vitro.Zhongguo Shi Yan Xue Ye Xue Za Zhi.2008,16(6):1372-5.
24. Kadam SS, Tiwari S, Bhonde RR. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord.In Vitro Cell Dev Biol Anim.2009,45(1-2):23-7.
25. Mihu CM, Mihu D, Costin N, et al. Isolation and characterization of stem cells from the placenta and the umbilical cord.Rom J Morphol Embryol. 2008,49(4):441-6.
26. Seshareddy K, Troyer D, Weiss ML. Method to isolate mesenchymal-like cells from Wharton's Jelly of umbilical cord.Methods Cell Biol. 2008,86:101-19.
27. Secco M, Zucconi E, Vieira NM, et al. Multipotent stem cells from umbilical cord:cord is richer than blood! Stem Cells.2008,26(1):146-50.
28. Guo Z, Yang J, Liu X, et al. Biological features ofmesenchymal stem cells from human bone marrow. Chin Med J (Engl).2001,114(9):950-3.
29. Wang YC, Zhang Y. Proliferative capacity of mesenchymal stem cells from humanfetal bone marrow and their ability to differentiate into the derivative cell types of three embryonic germ layers.Sheng Li Xue Bao. 2008,60(3):425-30.
1.Tse WT,Pendleton JD,Beyer WM,et al.Suppression of allogeneic T-cell proliferation by human marrow stromal cells:implications in transplantation.Transplantation 2003;75:389-397.
2.Majumdar MK,Keane-Moore M,Buyaner D,et al.Characterization and functionality of cell surface molecules on human mesenchymal stem cells.J Biomed Sci 2003;10:228-241.
3.Di Nicola M,Carlo-Stella C,Magni M,et al.Human bone marrow stromalcells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood 2002;99:3838-3843.
4.Beyth S,Borovsky Z,Mevorach D,et al.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood 2005; 105:2214-2219.
5.Krampera M,Glennie S,Dyson J,et al.Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.Blood2003;101:3722-3729.
6.Djouad F,Plence P,Bony C,et al.Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals.Blood 2003;102:3837-3844.
7.Di Nicola M,Carlo-Stella C,Magni M,et al.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood 2002;99:3838-3843.
8.He J,Zhang YJiang XX,et al.Effect of human bone marrow mesenchymal stem cell on cord blood T lymphocyte transformation.Zhongguo Shi Yan Xue Ye Xue43 Za Zhi 2003;11:11-14.
9.Chen JL,Guo ZK,Xu C,et al.Mesenchymal stem cells suppress allogeneic T cell responses by secretion of TGF-betal.Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002;10:285-288.
10.Krampera M,Glennie S,Dyson J,et al.Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.Blood 2003;101:3722-3729.
11.Tse WT,Pendleton JD,Beyer WM,et al.Suppression of allogeneic T-cell proliferation by human marrow stromal cells:implications in transplantation.Transplantation 2003;75:389-397.
12.Barry FP,Murphy JM,English K,et al.Immunogenicity of adult mesenchymal stem cells:lessons from the fetal allograft.Stem cells and development 2005;in press.
13.Le Blanc K,Rasmusson I,Gotherstrom C,et al.Mesenchymal stem cells inhibit the expression of CD25(interleukin-2 receptor)and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004;60:307-315.
14.Neuss S,Becher E,Woltje M,et al.Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization,tissue repair,and wound healing.Stem Cells 2004;22:405-414.
15.Rasmusson I,Ringden O,Sundberg B,et al.Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005;inpress.
1. Crop M, Baan C, Weimar W, Hoogduijn M. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int. 2009,22(4):365-76.
2. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol.2002,30(1):42-48.
3. Fibbe WE, Nauta AJ and Helene RS. Modulation of Immune Responses by Mesenchymal Stem Cells. Ann. N.Y. Acad. Sci.2007,1106:272-8.
4. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplant.1990,9(6):587-93.
5.庄聪文,翁向群,黄盛东,等.大鼠颈部异位心脏移植急性排斥反应的早期病理变化.东南国防医学.2005,7(3)：181-183.
6. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N Y Acad Sci.2009,1176:101-17.
7. Garcia-Castro J, Trigueros C, Madrenas J, et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med.2008,12(6B):2552-65.
8. Tong ZC, Yang Z, Tong ZQ, et al. Study of inducing bone marrow-derived mesenchymal stem cells into chondrocytes in vitro. Zhongguo Gu Shang. 2008,21(5):362-4.
9. Haack-Sorensen M, Friis T, Bindslev L, et al. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy. Scand J Clin Lab Invest.2008,68(3):192-203.
10. Gotherstrom C. Immunomodulation by multipotent mesenchymal stromal cells.Transplantation.2007,84(1 Suppl):S35-7.
11.TSEW T, PENDL ETON J D, BEYER W M, et al. Suppression of allogeneic T cell proliferation by human marrow stromal cells:implications in ransplantation[J]. Transplantation,2003,75(3):389-397.
12. Yang SH, Park MJ, Yoon IH, et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med. 2009,41(5):315-24.
13. Le BLANC K, TAMMIK L, SUNDBERG B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol,2003,57 (1):11-20.
14.唐伟,马建波,张陶然等.供体骨髓细胞输注促进小鼠皮肤移植耐受及其机理的研究.中华微生物学和免疫学杂志 2003,23(2)：143-147.
15.张庆殷,郝洁,郭宏伟等.门静脉输注供体脾细胞诱导异基因大鼠心脏移植耐受.免疫学杂志2001,17(4)：247-250.
16. Popp FC, Eggenhofer E, Renner P, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol.2008,20(1-2):55-60.
17. Zhang YN, Lie PC, Wei X. Differentiation of mesenchymal stromal cells derived from umbilical cordWharton's jelly into hepatocyte-like cells. Cytotherapy.2009,11(5):548-58.
18. Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008,26(11):2865-74.
19. Han ZC.Umbilical cord mesenchymal stem cells (UC-MSC:biology, banking and clinical applications).Bull Acad Natl Med.2009,193(3):545-7.
20. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003,101(8):2999-3001.
21. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003,102(10): 3837-44.
22. Eliopoulos N, Stagg J, Lejeune L, et al. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 2005,106(13):4057-65.
23. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006,108(6): 2114-20.
24. Poncelet AJ, Vercruysse J, Saliez A, et al. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007,83(6):783-90.
25. Popp FC, Slowik P, Eggenhofer E, et al. No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells 2007,25(3):639-45.
26. Yang CC, Shih YH, Ko MH, et al. Transplantation of human umbilical mesenchymal stem cells from Wharton's jelly after complete transection of the rat spinal cord. PLoS One.2008,3(10):e3336.
27. Tsai PC, Fu TW, Chen YM, et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Liver Transpl.2009,15(5):484-95.
28. PAWEL EC G, REHBEIN A, SCHLOTZ, et al. Cytokine modulation of TH1/TH2 phenotype differentiation indirectly alloresponsive CD4+human T cells. Transplantation,1996,62 (8):1095-1101.
29. DEVINE S M, COBBS C, J ENNIN GS M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood,2003,101(8):2999-3001.
30. ZHAN G W, GE W, L I C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev,2004,13 (3)263-271.
31. BEYTH S, BOROVSKY Z, MEVORACH D, et al. Human mesenchymal stem cells alter antigen presenting cell maturation and induce T cell unresponsiveness. Blood,2005,105:2214-2219.
32. A GGARWAL S, PITTENGER M F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood,2005,105(5):1815-1822.
33. MEISEL R, ZIBERT A, LARYEA M, et al. Human bone marrow st romal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood,2004,103 (12):4619-4621
1. Harzallah K, Abderrahim E, et al. Cancers after renal transplantation: multicenter experience.Saudi J Kidney Dis Transpl.2008;19(5):825-30.
2. Mueller AR, Platz KP, Schattenfroh N, et al. Neurotoxicity after orthotopic liver transplantation in cyclosporine A-and FK 506-treated patients. Transpl Int 1994; 7(suppl 1):S37-42.
3. Cattaneo D, Perico N, Gaspari F, et al. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004; 36(suppl 2):234S-239S.
4. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105 (4):1815-22.
5. Ringde'n O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81(10):1390-7.
6. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside:An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211(1):27-35.
7. Inoue S, Popp FC, Koehl GE, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81(11):1589-95.
8. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC:The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7(5):393-5.
9. Ko S, Deiwick A, Ja'ger MD, et al. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. Nat Med 1999; 5(11):1292-7.
10. Soulillou JP. Donor-specific transfusion-induced tolerance:Mechanisms revisited. Transplant Proc 1998; 30(5):2438-40.
11. Yang L, Du Temple B, Khan Q, et al. Mechanisms of long-term donorspecific allograft survival induced by pretransplant infusion of lymphocytes. Blood 1998; 91(1):324-30.
12. Devine SM, Bartholomew AM, Mahmud N, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29(2):244-55.
13. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101(8):2999-3001.
14. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102(10): 3837-44.
15. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101(9):3722-9.
16. Eliopoulos N, Stagg J, Lejeune L, et al. Allogeneic marrow stromal cells are immune rejected by MHC class Ⅰ-and class Ⅱ-mismatched recipient mice. Blood 2005; 106(13):4057-65.
17. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108(6): 2114-20.
18. Poncelet AJ, Vercruysse J, Saliez A, et al. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007; 83(6):783-90.
19. Popp FC, Slowik P, Eggenhofer E, et al. No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells 2007; 25(3):639-45.
20. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176(12):7761-7.
21. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99(10):3838-43.
22. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105(10):4120-6.
23. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4_ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90(4):516-25.
24. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3(3):199-210.
25. Lee MKIV, Moore DJ, Jarrett BP, et al. Promotion of allograft survival by CD4_CD25_ regulatory T cells:Evidence for in vivo inhibition of effector cell proliferation. J Immunol 2004; 172(11):6539-44.
26. Edinger M, Hoffmann P, Ermann J, et al. CD4 CD25_regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med 2003; 9(9):1144-50.
27. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109(1):228-34.
28. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation.Blood 2004; 103 (12):4619-21.
29. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176(11): 6752-61.
30. Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164 (7):3596-9.
31. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism.J Exp Med 1999; 189 (91):1363-72.
32. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297 (5588):1867-70.
33. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281 (5380):1191-3.
34. Bauer TM, Jiga LP, Chuang JJ, et al. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase:Tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 2005; 18(1) 95-100.
35. Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105 (7) 2821-7.
36. Gieseke F, Schu'tt B, Viebahn S, et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFN_R1-signaling and IDO expression. Blood 2007; 110 (6):2197-200.
37. Zhang W, Ge W, Li C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13 (3):263-71.
38. Abe K, Yarovinsky FO, Murakami T, et al. Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo.Blood 2003; 101 (4):1477-83.
39. Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of Thl/Th2 responses. Semin Immunol 2001; 13 (5):275-82.
40. Ritter U, Meissner A, Ott J, et al. Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-alpha reveals an essential role for TNF. JLeukoc Biol 2003; 74 (2):216-22.
41. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.
42. Nauta AJ, Kruisselbrink AB, Lurvink E, et al. Mesenchymal stem cells inhibit generation and function of both CD34_-derived and monocytederived dendritic cells. J Immunol 2006; 177 (4):2080-7.
43. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood 2005; 105 (5):2214-9.
44. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107(12):4817-24.
45. Romieu-Mourez R, Francois M, Boivin MN, et al. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-_, TGF-_, and cell density. J Immunol 2007; 179(3): 1549-58.
46. Stagg J, Pommey S, Eliopoulos N, et al. Interferon-gamma-stimulated marrow stromal cells:A new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107(6):2570-7.
47. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30(1):42-8.
48. Zhou HP, Yi DH, Yu SQ, et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006; 38(9):3046-51.
49. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7(8):610-21.
2. Jiang Y, Jahagirdar BN, Reinhardt RL,et al.Pluripotency of mesenchymal stem cells derived from adult marrow.Nature.2002,418(6893):41-9.
3. Pittenger MF,Martin BJ.Mesenchymal stem cells and their potential as cardiac therapeutics.Circ Res 2004,95(1):9-20.
4. Schwartz RE,Reyes M,Koodie L,et al.Mutipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells.J Clin Invest 2002,109(10):1291-1302.
5. Satake K,Lou J,Lenke LGMigration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue. Spine 2004, 29(18):1971-1979.
6. DEANS R J, MOSEL EY A B. Mesenchymal stem cells:Biology and potential clinical uses[J]. Exp Hematol,2000,28(8):875-884.
7. TSEW T, PENDL ETON J D, BEYER W M, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells:implications in ransplantation. Transplantation,2003,75(3):389-397.
8..KL YUSHNEN KOVA E, SHUSTOVA V, MOSCA J D, et al. Human mesenchymal stem cells induce unresponsiveness in preactivated but not naive alloantigen specific T cells [J]. Exp Hematol,1999,27(30:122-122.
9. Le BLANC K, TAMMIK L, SUNDBERG B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol,2003,57(1):11-20.
10.唐伟,马建波,张陶然等.供体骨髓细胞输注促进小鼠皮肤移植耐受及其机理的研究.中华微生物学和免疫学杂志2003,23(2)：143-147。
11.张庆殷,郝洁,郭宏伟等.门静脉输注供体脾细胞诱导异基因大鼠心脏移 植耐受.免疫学杂志2001,17(4)：247-250.
12. Han Q,Deng W,Li C,et al.Allogeneic adult stem cells establish long-term residence in recipient tissues and facilitate skin transplantation.Exp Hematol 2003,31(9):158-159.
13. Rao MS,Matton MP. Stem cells and aging expanding the possibilities.Mech Ageing Dev 2001,122(7):713-734.
14. Barry FP, Murphy JM. Mesenchymal stem cells:clinical applications andbiological characterization.Int J Biochem Cell Biol 2004,36(4):568-84.
15. Hu Y,Liao LM,Wang QY,et al.Isolation and identification of mesenchymal stem cells from human fetal pancreas.J Lab Clin Med 2003,141(5):342-349.
16. In't Anker PS,Noort WA,Scherjon SA,et al.Mesenchymal stem cells in human second-trimester bone marrow,liver,lung,and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 2003,88(8):845-852.
17. Lee OK,Kuo TK,Chen WM,et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood.Blood 2004,103(5):1669-1675.
18. Romanov YA,Svintsitskaya VA,Smirnov VN.Searching for alternative sources of postnatal human mesenchymal stem cells:candidate MSC-like cells from umbilical cord.Stem Cells 2003,21(1):105-110.14.
19. Bartholomew A,Sturgeon C,Siatskas M,et al.Mesenchymal stem cells suppress 40 lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol 2002,30(1):42-48.
20. Wexler SA,Donaldson C,Denning-Kendall P,et al.Adult bone marrow is a rich source of human mesenchymal'stem'cells but umbilical cord and mobilized adult blood are not.Br J Haematol 2003,121(2):368-374.
21.吕璐璐,刘拥军,许贞书,等.脐带源间充质干细胞的分离和生物学形状.福建医科大学学报.2006.,40(2)：99-104.
22.张浪辉,刘拥军,吕璐璐,等.脐带源间充质干细胞对异源性脐带血T淋巴细胞激活与增殖的抑制作用[J].中国肿瘤生物治疗杂志,2006,13(3)： 191-195.
1. Sbano P, Cuccia A, Mazzanti B, et al.Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res.2008,300(3):115-24.
2. Itakura S, Asari S, Rawson J, et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant.2007,7(2):336-46.
3. Miyazaki M, Zuk PA, Zou J, et al. Comparison of human mesenchymal stem cells derived from adipose tissue and bone marrow for ex vivo gene therapy in rat spinal fusion model. Spine (Phila Pa 1976).2008,33(8):863-9.
4. Parr AM, Kulbatski I, Wang XH, et al. Fate of transplanted adult neural stem/progenitor cells and bone marrow-derived mesenchymal stromal cells in the injured adult rat spinal cord and impact on functional recovery.Surg Neurol.2008,70(6):600-7.
5. Zhang YH, Wang HF, Liu W, et al. Insulin-producing cells derived from rat bone marrow and their autologous transplantation in the duodenal wall for treating diabetes.Anat Rec (Hoboken).2009,292(5):728-35.
6. Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells:candidate MSC-like cells from umbilical cord. Stem Cells.2003,21(1):105-110.
7. Covas DT, Siufi JL, Silva AR, et al. Isolation and culture of umbilical vein mesenchymal stem cells. Braz J Med Biol Res.2003,36(9):1179-1183.
8. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells.2004,22(7):1330-1337.
9. Sarugaser R, Lickorish D, Baksh D, et al. Human umbilical cord perivascular (HUCPV) cells:a source of mesenchymal progenitors. Stem Cells,2005,23(2):220-229.
10. Ennis J, Gotherstrom C, Le Blanc K, et al. In vitro immunologic properties of human umbilical cord perivascular cells. Cytotherapy.2008,10(2):174-81
11. Hu Y, Liao L, Wang Q, et al. Isolation and identification of mesenchymal stem cells from human fetal pancreas. J Lab Clin Med.2003,141(5):342-349.
12. Anker PS, Noort WA, Scherjon SA, et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica.2003,88(8):845-852.
13. Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004,103(5):1669-1675.
14. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol.2002,30(1):42-48.
15. Wexler SA, Donaldson C, Denning-Kendall P, et al. Adult bone marrow is a rich source of human mesenchymal'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol.2003,121(2):368-374.
16.吕璐璐,刘拥军,许贞书,等.脐带源间充质干细胞的分离和生物学形状[J].福建医科大学学报,2006,40(2)：28-30.
17.张浪辉,刘拥军,吕璐璐,等.脐带源间充质干细胞对异源性脐带血T淋巴细胞激活与增殖的抑制作用[J].中国肿瘤生物治疗杂志,2006,13(3)：191-195.
18. Cao FJ, Feng SQ. Human umbilical cord mesenchymal stem cells and the treatmentof spinal cord injury. Chin Med J (Engl).2009,122(2):225-31.
19. Friedman R, Betancur M, Boissel L, et al. Umbilical cord mesenchymal stem cells:adjuvants for human cell transplantation. Biol Blood Marrow Transplant.2007,13(12):1477-86.
20. Yang CC, Shih YH, Ko MH, et al. Transplantation of humanumbilical mesenchymal stem cells from Wharton's jelly after complete transection of the rat spinal cord. PLoS One.2008,3(10):e3336.
21. Kadam SS, Tiwari S, Bhonde RR. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord. In Vitro Cell Dev Biol Anim.2009,45(1-2):23-7.
22. Ding DC, Shyu WC, Chiang MF, et al. Enhancement of neuroplasticity through upregulation of betal-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis.2007,27(3):339-53.
23. Qiu ZY, Yang SG, Chen ZP, et al. Mesenchymal stem cells derived from human umbilical cord tissue modulate thesecretion of antiplatelet antibody from splenocytes of ITP patients in vitro.Zhongguo Shi Yan Xue Ye Xue Za Zhi.2008,16(6):1372-5.
24. Kadam SS, Tiwari S, Bhonde RR. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord.In Vitro Cell Dev Biol Anim.2009,45(1-2):23-7.
25. Mihu CM, Mihu D, Costin N, et al. Isolation and characterization of stem cells from the placenta and the umbilical cord.Rom J Morphol Embryol. 2008,49(4):441-6.
26. Seshareddy K, Troyer D, Weiss ML. Method to isolate mesenchymal-like cells from Wharton's Jelly of umbilical cord.Methods Cell Biol. 2008,86:101-19.
27. Secco M, Zucconi E, Vieira NM, et al. Multipotent stem cells from umbilical cord:cord is richer than blood! Stem Cells.2008,26(1):146-50.
28. Guo Z, Yang J, Liu X, et al. Biological features ofmesenchymal stem cells from human bone marrow. Chin Med J (Engl).2001,114(9):950-3.
29. Wang YC, Zhang Y. Proliferative capacity of mesenchymal stem cells from humanfetal bone marrow and their ability to differentiate into the derivative cell types of three embryonic germ layers.Sheng Li Xue Bao. 2008,60(3):425-30.
1.Tse WT,Pendleton JD,Beyer WM,et al.Suppression of allogeneic T-cell proliferation by human marrow stromal cells:implications in transplantation.Transplantation 2003;75:389-397.
2.Majumdar MK,Keane-Moore M,Buyaner D,et al.Characterization and functionality of cell surface molecules on human mesenchymal stem cells.J Biomed Sci 2003;10:228-241.
3.Di Nicola M,Carlo-Stella C,Magni M,et al.Human bone marrow stromalcells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood 2002;99:3838-3843.
4.Beyth S,Borovsky Z,Mevorach D,et al.Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood 2005; 105:2214-2219.
5.Krampera M,Glennie S,Dyson J,et al.Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.Blood2003;101:3722-3729.
6.Djouad F,Plence P,Bony C,et al.Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals.Blood 2003;102:3837-3844.
7.Di Nicola M,Carlo-Stella C,Magni M,et al.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood 2002;99:3838-3843.
8.He J,Zhang YJiang XX,et al.Effect of human bone marrow mesenchymal stem cell on cord blood T lymphocyte transformation.Zhongguo Shi Yan Xue Ye Xue43 Za Zhi 2003;11:11-14.
9.Chen JL,Guo ZK,Xu C,et al.Mesenchymal stem cells suppress allogeneic T cell responses by secretion of TGF-betal.Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002;10:285-288.
10.Krampera M,Glennie S,Dyson J,et al.Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.Blood 2003;101:3722-3729.
11.Tse WT,Pendleton JD,Beyer WM,et al.Suppression of allogeneic T-cell proliferation by human marrow stromal cells:implications in transplantation.Transplantation 2003;75:389-397.
12.Barry FP,Murphy JM,English K,et al.Immunogenicity of adult mesenchymal stem cells:lessons from the fetal allograft.Stem cells and development 2005;in press.
13.Le Blanc K,Rasmusson I,Gotherstrom C,et al.Mesenchymal stem cells inhibit the expression of CD25(interleukin-2 receptor)and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004;60:307-315.
14.Neuss S,Becher E,Woltje M,et al.Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization,tissue repair,and wound healing.Stem Cells 2004;22:405-414.
15.Rasmusson I,Ringden O,Sundberg B,et al.Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005;inpress.
1. Crop M, Baan C, Weimar W, Hoogduijn M. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int. 2009,22(4):365-76.
2. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol.2002,30(1):42-48.
3. Fibbe WE, Nauta AJ and Helene RS. Modulation of Immune Responses by Mesenchymal Stem Cells. Ann. N.Y. Acad. Sci.2007,1106:272-8.
4. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplant.1990,9(6):587-93.
5.庄聪文,翁向群,黄盛东,等.大鼠颈部异位心脏移植急性排斥反应的早期病理变化.东南国防医学.2005,7(3)：181-183.
6. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N Y Acad Sci.2009,1176:101-17.
7. Garcia-Castro J, Trigueros C, Madrenas J, et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med.2008,12(6B):2552-65.
8. Tong ZC, Yang Z, Tong ZQ, et al. Study of inducing bone marrow-derived mesenchymal stem cells into chondrocytes in vitro. Zhongguo Gu Shang. 2008,21(5):362-4.
9. Haack-Sorensen M, Friis T, Bindslev L, et al. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy. Scand J Clin Lab Invest.2008,68(3):192-203.
10. Gotherstrom C. Immunomodulation by multipotent mesenchymal stromal cells.Transplantation.2007,84(1 Suppl):S35-7.
11.TSEW T, PENDL ETON J D, BEYER W M, et al. Suppression of allogeneic T cell proliferation by human marrow stromal cells:implications in ransplantation[J]. Transplantation,2003,75(3):389-397.
12. Yang SH, Park MJ, Yoon IH, et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med. 2009,41(5):315-24.
13. Le BLANC K, TAMMIK L, SUNDBERG B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol,2003,57 (1):11-20.
14.唐伟,马建波,张陶然等.供体骨髓细胞输注促进小鼠皮肤移植耐受及其机理的研究.中华微生物学和免疫学杂志 2003,23(2)：143-147.
15.张庆殷,郝洁,郭宏伟等.门静脉输注供体脾细胞诱导异基因大鼠心脏移植耐受.免疫学杂志2001,17(4)：247-250.
16. Popp FC, Eggenhofer E, Renner P, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol.2008,20(1-2):55-60.
17. Zhang YN, Lie PC, Wei X. Differentiation of mesenchymal stromal cells derived from umbilical cordWharton's jelly into hepatocyte-like cells. Cytotherapy.2009,11(5):548-58.
18. Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008,26(11):2865-74.
19. Han ZC.Umbilical cord mesenchymal stem cells (UC-MSC:biology, banking and clinical applications).Bull Acad Natl Med.2009,193(3):545-7.
20. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003,101(8):2999-3001.
21. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003,102(10): 3837-44.
22. Eliopoulos N, Stagg J, Lejeune L, et al. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 2005,106(13):4057-65.
23. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006,108(6): 2114-20.
24. Poncelet AJ, Vercruysse J, Saliez A, et al. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007,83(6):783-90.
25. Popp FC, Slowik P, Eggenhofer E, et al. No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells 2007,25(3):639-45.
26. Yang CC, Shih YH, Ko MH, et al. Transplantation of human umbilical mesenchymal stem cells from Wharton's jelly after complete transection of the rat spinal cord. PLoS One.2008,3(10):e3336.
27. Tsai PC, Fu TW, Chen YM, et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Liver Transpl.2009,15(5):484-95.
28. PAWEL EC G, REHBEIN A, SCHLOTZ, et al. Cytokine modulation of TH1/TH2 phenotype differentiation indirectly alloresponsive CD4+human T cells. Transplantation,1996,62 (8):1095-1101.
29. DEVINE S M, COBBS C, J ENNIN GS M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood,2003,101(8):2999-3001.
30. ZHAN G W, GE W, L I C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev,2004,13 (3)263-271.
31. BEYTH S, BOROVSKY Z, MEVORACH D, et al. Human mesenchymal stem cells alter antigen presenting cell maturation and induce T cell unresponsiveness. Blood,2005,105:2214-2219.
32. A GGARWAL S, PITTENGER M F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood,2005,105(5):1815-1822.
33. MEISEL R, ZIBERT A, LARYEA M, et al. Human bone marrow st romal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood,2004,103 (12):4619-4621
1. Harzallah K, Abderrahim E, et al. Cancers after renal transplantation: multicenter experience.Saudi J Kidney Dis Transpl.2008;19(5):825-30.
2. Mueller AR, Platz KP, Schattenfroh N, et al. Neurotoxicity after orthotopic liver transplantation in cyclosporine A-and FK 506-treated patients. Transpl Int 1994; 7(suppl 1):S37-42.
3. Cattaneo D, Perico N, Gaspari F, et al. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004; 36(suppl 2):234S-239S.
4. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105 (4):1815-22.
5. Ringde'n O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81(10):1390-7.
6. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside:An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211(1):27-35.
7. Inoue S, Popp FC, Koehl GE, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81(11):1589-95.
8. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC:The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7(5):393-5.
9. Ko S, Deiwick A, Ja'ger MD, et al. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. Nat Med 1999; 5(11):1292-7.
10. Soulillou JP. Donor-specific transfusion-induced tolerance:Mechanisms revisited. Transplant Proc 1998; 30(5):2438-40.
11. Yang L, Du Temple B, Khan Q, et al. Mechanisms of long-term donorspecific allograft survival induced by pretransplant infusion of lymphocytes. Blood 1998; 91(1):324-30.
12. Devine SM, Bartholomew AM, Mahmud N, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29(2):244-55.
13. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101(8):2999-3001.
14. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102(10): 3837-44.
15. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101(9):3722-9.
16. Eliopoulos N, Stagg J, Lejeune L, et al. Allogeneic marrow stromal cells are immune rejected by MHC class Ⅰ-and class Ⅱ-mismatched recipient mice. Blood 2005; 106(13):4057-65.
17. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108(6): 2114-20.
18. Poncelet AJ, Vercruysse J, Saliez A, et al. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007; 83(6):783-90.
19. Popp FC, Slowik P, Eggenhofer E, et al. No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells 2007; 25(3):639-45.
20. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176(12):7761-7.
21. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99(10):3838-43.
22. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105(10):4120-6.
23. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4_ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90(4):516-25.
24. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3(3):199-210.
25. Lee MKIV, Moore DJ, Jarrett BP, et al. Promotion of allograft survival by CD4_CD25_ regulatory T cells:Evidence for in vivo inhibition of effector cell proliferation. J Immunol 2004; 172(11):6539-44.
26. Edinger M, Hoffmann P, Ermann J, et al. CD4 CD25_regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med 2003; 9(9):1144-50.
27. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109(1):228-34.
28. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation.Blood 2004; 103 (12):4619-21.
29. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176(11): 6752-61.
30. Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164 (7):3596-9.
31. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism.J Exp Med 1999; 189 (91):1363-72.
32. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297 (5588):1867-70.
33. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281 (5380):1191-3.
34. Bauer TM, Jiga LP, Chuang JJ, et al. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase:Tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 2005; 18(1) 95-100.
35. Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105 (7) 2821-7.
36. Gieseke F, Schu'tt B, Viebahn S, et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFN_R1-signaling and IDO expression. Blood 2007; 110 (6):2197-200.
37. Zhang W, Ge W, Li C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13 (3):263-71.
38. Abe K, Yarovinsky FO, Murakami T, et al. Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo.Blood 2003; 101 (4):1477-83.
39. Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of Thl/Th2 responses. Semin Immunol 2001; 13 (5):275-82.
40. Ritter U, Meissner A, Ott J, et al. Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-alpha reveals an essential role for TNF. JLeukoc Biol 2003; 74 (2):216-22.
41. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.
42. Nauta AJ, Kruisselbrink AB, Lurvink E, et al. Mesenchymal stem cells inhibit generation and function of both CD34_-derived and monocytederived dendritic cells. J Immunol 2006; 177 (4):2080-7.
43. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood 2005; 105 (5):2214-9.
44. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107(12):4817-24.
45. Romieu-Mourez R, Francois M, Boivin MN, et al. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-_, TGF-_, and cell density. J Immunol 2007; 179(3): 1549-58.
46. Stagg J, Pommey S, Eliopoulos N, et al. Interferon-gamma-stimulated marrow stromal cells:A new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107(6):2570-7.
47. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30(1):42-8.
48. Zhou HP, Yi DH, Yu SQ, et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006; 38(9):3046-51.
49. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7(8):610-21.